Healthcare stocks are facing significant challenges in 2026, with the sector experiencing a year-to-date loss of approximately 6%, making it the worst performer among the S&P 500’s 11 sectors. This downturn has affected major pharmaceutical companies and mid-cap stocks like Hims & Hers Health (HIMS), which has seen a decline of over 23% this year despite a recent rally of nearly 32% in the past month. The volatility in HIMS shares was evident after a brief spike following a favorable FDA announcement, only to see the stock drop as traders took profits.
As Hims & Hers prepares to report Q1 earnings on May 11, investors are keenly focused on subscriber growth and the impact of its partnership with Novo Nordisk, which allows the company to sell popular GLP-1 products. Analysts anticipate a significant year-over-year decline in earnings per share, with estimates around three to four cents, and revenue forecasts between $616 million and $619 million. A strong performance could shift market sentiment, while a miss may exacerbate selling pressure.
Investors should closely monitor the upcoming earnings report, as it could provide critical insights into Hims & Hers’ growth trajectory and overall market sentiment towards healthcare stocks. With a consensus hold rating and a substantial short interest, any positive surprises could catalyze a shift in the stock’s trajectory, potentially driving it closer to the average price target of $32.
Source: marketbeat.com